BACKGROUND
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population-level outcomes remain...
M. Brink, Arie C. van der Spek, J. Doorduijn et al.· European Journal of Haematol...· 0 citations
It is demonstrated that ctDNA could potentially be used for prognostication and disease monitoring in PTLD, outperforming PET/CT in 8 cases, indicating that ctDNA monitoring can complement PET/CT to guide early escalation to chemotherapy in high-risk patients, though larger cohorts are needed to validate these findings...
Y. Zhong, Nick Veltmaat, Filipe Montes de Jesus et al.· Blood Advances· 0 citations
BACKGROUND
Chemotherapy-free regimens, such as rituximab and lenalidomide, are attractive first-line treatment options for follicular lymphoma, but combinations providing deeper, more durable responses are needed. We aimed to assess 3-year activity and safety of epcoritamab, a subcutaneously administered CD3 × CD20 bis...
L. Falchi, J. Vermaat, Joshua D. Brody et al.· The Lancet Haematology· 0 citations
Background/Objectives: Patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are at high risk for severe disease and treatment-related complications and toxicities. Pharmacogenetic studies suggest that genetic variants can...
Lea P. A. Timmann, Pauline Lanting, L. Morsink et al.· Hemato· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
